For example, combining HSV-TK/GCV with immune checkpoint inhibitors, radiation or other targeted therapies (e.g., histone deacetylase inhibitors and valproic acid) can synergize to produce more robust anti-tumour responses, potentially overcoming resistance mechanisms and improving treatment outcomes [228,229,230]. The gene discussed is TKT; the disease is neoplasm.